Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

ABSTRACT:

Objectives

Autoreactive memory B cells (MBCs) contribute to chronic and progressive courses in autoimmune diseases like SLE. The efficacy of belimumab (BEL), the first approved biologic treatment for SLE and LN, is generally attributed to depletion of activated naïve B cells and inhibition of B-cell activation. BEL's effect on MBCs is currently unexplained. We performed an in-depth cellular and transcriptomic analysis of BEL's impact on the blood MBC compartment in patients with SLE.

Methods

A retrospective meta-analysis was conducted, pooling flow cytometry data from four randomized trials involving 1245 patients with SLE treated with intravenous BEL or placebo. Then, extensive MBC phenotyping was performed using high-sensitivity flow cytometry in patients with mild/moderat

SUBMITTER: Arends EJ 

PROVIDER: S-EPMC11371378 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature